SCM
ACRS icon

Suffolk Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Suffolk Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-54,063
Closed -$1.4M – 124
2017
Q3 		$1.4M Sell
54,063
-181
-0.3% -$4.85K 0.18% 67
2017
Q2 		$1.47M Buy
+54,244
New +$1.47M 0.19% 97

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Suffolk Capital Management's ACRS Position: Q4 2017 in Review

Suffolk Capital Management sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 54,063 shares — an estimated $1.4M sold.

Suffolk Capital Management first reported a position in ACRS in Q2 2017 and held it in 2 quarters. The position peaked at $1.47M in Q2 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Suffolk Capital Management reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 54,063 Aclaris Therapeutics shares in Q4 2017, an estimated $1.4M.
  • Suffolk Capital Management first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 2 quarters.
  • Suffolk Capital Management's Aclaris Therapeutics position peaked at $1.47M in Q2 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Suffolk Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.